Free Trial

Johnson & Johnson (NYSE:JNJ) Trading 0.3% Higher - What's Next?

Johnson & Johnson logo with Medical background

Johnson & Johnson (NYSE:JNJ - Get Free Report) shares rose 0.3% during trading on Thursday . The stock traded as high as $147.77 and last traded at $147.03. Approximately 1,681,589 shares were traded during trading, a decline of 76% from the average daily volume of 7,099,400 shares. The stock had previously closed at $146.64.

Analyst Ratings Changes

A number of equities research analysts have weighed in on JNJ shares. Morgan Stanley boosted their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 16th. Bank of America reiterated a "neutral" rating and set a $166.00 price target on shares of Johnson & Johnson in a research note on Tuesday. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday. Wolfe Research began coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an "outperform" rating and a $190.00 target price for the company. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $174.73.

Get Our Latest Report on Johnson & Johnson

Johnson & Johnson Price Performance

The stock has a fifty day moving average of $157.29 and a two-hundred day moving average of $156.35. The stock has a market cap of $352.07 billion, a price-to-earnings ratio of 21.28, a price-to-earnings-growth ratio of 2.66 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business's revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.66 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date of this dividend was Tuesday, November 26th. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Institutional Trading of Johnson & Johnson

Several institutional investors and hedge funds have recently modified their holdings of the business. Vinva Investment Management Ltd boosted its stake in shares of Johnson & Johnson by 6.8% during the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock valued at $17,988,000 after acquiring an additional 7,110 shares during the last quarter. Financial Counselors Inc. grew its holdings in shares of Johnson & Johnson by 5.3% during the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock worth $29,996,000 after buying an additional 9,309 shares in the last quarter. Meridian Financial Partners LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $1,626,000. Meridian Investment Counsel Inc. lifted its stake in shares of Johnson & Johnson by 19.6% during the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock valued at $3,667,000 after buying an additional 3,710 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in Johnson & Johnson by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock worth $2,858,543,000 after acquiring an additional 102,502 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Should you invest $1,000 in Johnson & Johnson right now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Future of Healthcare: 3 AI Stocks Leading the Way
Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines